Scl-70 Scleroderma Antibody is a blood test that detects antibodies against topoisomerase I, also known as Scl-70. These autoantibodies are associated particularly with systemic sclerosis (scleroderma). The test is needed to support the evaluation of individuals with symptoms suggestive of systemic sclerosis, such as skin thickening, Raynaud’s phenomenon, or other organ involvement. Results are interpreted alongside clinical findings and other autoimmune tests.
Systemic sclerosis is an autoimmune condition that can cause hardening and thickening of the skin and may affect internal organs, including the lungs, kidneys, heart, and digestive system.
A positive result indicates that Scl-70 antibodies have been detected. In the appropriate clinical setting, this can support a diagnosis of systemic sclerosis.
No. The result should not be interpreted on its own. Diagnosis is based on clinical features, physical examination, antibody testing, and other investigations.
A negative result means Scl-70 antibodies were not detected. However, systemic sclerosis cannot be completely ruled out because not all affected individuals have Scl-70 antibodies.
Raynaud’s phenomenon causes fingers or toes to change colour and become cold or painful in response to cold temperatures or stress. It can occur independently or as part of an autoimmune condition.